Advertisement

Increased risk of brain metastases in ovarian cancer patients with BRCA mutations

      Highlights

      • BRCA mutations may be associated with brain metastases in ovarian cancer.
      • Real-world data were used to estimate ovarian cancer brain metastases risk.
      • We assessed if BRCA mutation increases brain metastases risk in ovarian cancer.
      • BRCA mutation increased the risk of brain metastases by 4-fold versus BRCA wildtype.
      • Diagnosis of brain metastases was 8 months earlier with BRCA mutation.

      Abstract

      Purpose

      To estimate the risk for brain metastases in patients with ovarian cancer using real-world data, and assess whether BRCA mutations increase that risk.

      Methods

      This retrospective study included 4515 patients diagnosed with ovarian cancer between January 1, 2011, and January 31, 2018, from the Flatiron Health database, a longitudinal, demographically, and geographically diverse database derived from electronic health records in the United States.

      Results

      Forty-six (1%) patients were diagnosed with brain metastases after being diagnosed with ovarian cancer. Of 4515 patients with ovarian cancer, 10% had a known BRCA mutation, 37% had BRCA wildtype (BRCAwt), and the BRCA status of the remaining 51% was unknown/untested. Brain metastases were observed in 3% of patients with BRCA mutations compared with 0.6% of those with BRCAwt. The Kaplan-Meier estimate for the proportion of patients with brain metastases within 5 years of diagnosis was 5.7% in the population with BRCA mutations compared with 1.4% in those with BRCAwt (hazard ratio 4.44; 95% confidence interval, 1.97, 10.00; P < 0.0001). These data demonstrate that patients with a BRCA mutation had a significantly higher risk for brain metastases than those without.

      Conclusion

      Despite being a rare manifestation of ovarian cancer, the possibility of developing brain metastases should be considered in these patients, especially in patients with a BRCA mutation. The availability of new therapeutic options that may prolong overall survival and may not cross the blood–brain barrier could also lead to an increase in brain metastases in patients with ovarian cancer.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Gynecologic Oncology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • National Cancer Institute
        Cancer Stat Facts: Ovarian Cancer.
        2018
      1. K.B. Kuchenbaecker, J.L. Hopper, D.R. Barnes, K.A. Phillips, T.M. Mooij, M.J. Roos-Blom, et al, Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers, JAMA. 317 (2017) 2402–2416.

        • Osman M.A.
        Genetic cancer ovary.
        Clin. Ovarian Other Gynecol. Cancer. 2014; 7: 1-7
        • Wooster R.
        • Weber B.L.
        Breast and ovarian cancer.
        N. Engl. J. Med. 2003; 348: 2339-2347
        • Gudmundsdottir K.
        • Ashworth A.
        The roles of BRCA1 and BRCA2 and associated proteins in the maintenance of genomic stability.
        Oncogene. 2006; 25: 5864-5874
      2. J.M. Cunningham, M.S. Cicek, N.B. Larson, J. Davila, C. Wang, M.C. Larson, et al, Clinical characteristics of ovarian cancer classified by BRCA1, BRCA2, and RAD51C status, Sci. Rep. 4 (2014) 4026.

        • Pakneshan S.
        • Safarpour D.
        • Tavassoli F.
        • Jabbari B.
        Brain metastasis from ovarian cancer: a systematic review.
        J. Neuro-Oncol. 2014; 119: 1-6
        • Pietzner K.
        • Oskay-Oezcelik G.
        • El Khalfaoui K.
        • Boehmer D.
        • Lichtenegger W.
        • Sehouli J.
        Brain metastases from epithelial ovarian cancer: overview and optimal management.
        Anticancer Res. 2009; 29: 2793-2798
        • Pectasides D.
        • Pectasides M.
        • Economopoulos T.
        Brain metastases from epithelial ovarian cancer: a review of the literature.
        Oncologist. 2006; 11: 252-260
        • Piura E.
        • Piura B.
        Brain metastases from ovarian carcinoma.
        ISRN Oncol. 2011; 2011527453
      3. D.F. Kolomainen, J.M. Larkin, M. Badran, R.P. A'Hern, D.M. King, C. Fisher C, et al, Epithelial ovarian cancer metastasizing to the brain: a late manifestation of the disease with an increasing incidence, J. Clin. Oncol. 20 (2002) 982–986.

        • Sekine M.
        • Yoshihara K.
        • Komata D.
        • Haino K.
        • Nishino K.
        • Tanaka K.
        Increased incidence of brain metastases in BRCA1-related ovarian cancers.
        J. Obstet. Gynaecol. Res. 2013; 39: 292-296
      4. S. Balendran, S. Liebmann-Reindl, A.S. Berghoff, T. Reischer, N. Popitsch, C.B. Geier, et al, Next-generation sequencing-based genomic profiling of brain metastases of primary ovarian cancer identifies high number of BRCA-mutations, J. Neuro-Oncol. 133 (2017) 469–476.

        • Root K.
        • Armaghany T.
        Solitary brain metastasis in a patient with ovarian cancer with BRCA2 mutation.
        J. Clin. Oncol. 2012; 30: e239-e240
        • Han C.H.
        • Brastianos P.K.
        Genetic characterization of brain metastases in the era of targeted therapy.
        Front. Oncol. 2017; 7: 230
        • National Cancer Institute
        Breast Cancer Treatment (PDQ®)–Health Professional Version.
        2018
        • Zavitsanos P.J.
        • Wazer D.E.
        • Hepel J.T.
        • Wang Y.
        • Singh K.
        • Leonard K.L.
        BRCA1 mutations associated with increased risk of brain metastases in breast cancer: a 1: 2 matched-pair analysis.
        Am. J. Clin. Oncol. 2018; 41: 1252-1256
      5. L. J. Lee, B. Alexander, S.J. Schnitt, A. Comander, B. Gallagher, J.E. Garber, et al, Clinical outcome of triple negative breast cancer in BRCA1 mutation carriers and noncarriers, Cancer. 117 (2011) 3093–3100.

        • Albiges L.
        • André F.
        • Balleyguier C.
        • Gomez-Abuin G.
        • Chompret A.
        • Delaloge S.
        Spectrum of breast cancer metastasis in BRCA1 mutation carriers: highly increased incidence of brain metastases.
        Ann. Oncol. 2005; 16: 1846-1847
        • Jordan E.J.
        • Lowery M.A.
        • Basturk O.
        • Allen P.J.
        • Yu K.H.
        • Tabar V.
        Brain metastases in pancreatic ductal adenocarcinoma: assessment of molecular genotype-phenotype features-an entity with an increasing incidence?.
        Clin. Colorectal Cancer. 2018; 17: e315-e321
        • Hauck C.R.
        • Thibodeau B.J.
        • Ahmed S.
        • Johnson M.D.
        • Wilson G.D.
        Targeted DNA sequencing of nonsmall cell lung cancer identifies mutations associated with brain metastases.
        Int. J. Radiat. Oncol. Biol. Phys. 2017; 99: S199-S200
      6. A. Antoniou, P.D.P. Pharoah, S. Narod, H.A. Risch, J.E. Eyfjord, J.L. Hopper, et al, Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies, Am. J. Hum. Genet. 72 (2003) 1117–1130.